1.Klein CA. Cancer progression and the invisible phase of metastatic colonization. Nat Rev Cancer. 2020; 20(11): 681–694.
2.Wang S, Liu Y, Feng Y, et al. A review on curability of cancers: more efforts for novel therapeutic options are needed. Cancers. 2019; 11(11): 1782. doi: 10.3390/cancers11111782
3.Ao Z. Study of the Role of Circulating Tumor Cells (CTC) and Circulating Cellular Microenvironment Components in Metastasis Formation and their Clinical Value [Dissertation]. Coral Gables, FL, USA: University of Miami; 2015.
4.De Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023; 41(3): 374–403. doi: 10.1016/j.ccell.2023.02.016
5.Celià-Terrassa T, Kang Y. Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 2018; 20(8): 868–877. doi: 10.1038/s41556-018-0145-9
6.Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2): 117–134. doi: 10.1016/j.jconrel.2012.03.020
7.Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011; 14(1): 67–77. doi: 10.18433/j30c7d
8.Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021; 11(8): 771. doi: 10.3390/jpm11080771
9.Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015; 91: 3–6. doi: 10.1016/j.addr.2015.01.002
10.Cheng YH, He C, Riviere JE, et al. Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach. ACS Nano. 2020; 14(3): 3075–3095. doi: 10.1021/acsnano.9b08142
11.Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, et al. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. BMJ Oncol. 2025; 4(1): e000573. doi: 10.1136/bmjonc-2024-000573
12.Jacot W, Pons E, Frenel JS, et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat. 2016; 157(2): 307–318. doi: 10.1007/s10549-016-3828-6
13.Rubens R. Bone metastases—the clinical problem. Eur J Cancer. 1998; 34(2): 210–213. doi: 10.1016/s0959-8049(97)10135-3
14.Guan Y, Zhang W, Mao Y, et al. Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment. Mol Cancer. 2024; 23(1): 246. doi: 10.1186/s12943-024-02158-4
15.Kumamoto H, Ooya K. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med. 2004; 33(1): 46–52. doi: 10.1111/j.1600-0714.2004.00180.x
16.Ingole VH, Ghule SS, Vuherer T, et al. Mechanical properties of differently nanostructured and high-pressure compressed hydroxyapatite-based materials for bone tissue regeneration. Minerals. 2021; 11(12): 1390. doi: 10.3390/min11121390
17.Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem Res. 2009; 34(12): 2067–2077. doi: 10.1007/s11064-009-0081-y
18.Pandey V, Pandey T. Mechanistic understanding of pH as a driving force in cancer therapeutics. J Mater Chem B. 2025; 13(8): 2640–2657. doi: 10.1039/d4tb02291a
19.Allocati N, Masulli M, Di Ilio C, et al. Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018; 7(1): 8. doi: 10.1038/s41389-017-0025-3
20.Cogger VC, Hunt NJ, Le Couteur DG. Fenestrations in the liver sinusoidal endothelial cell. In: The Liver: Biology and Pathobiology. Hoboken, NJ, USA: John Wiley & Sons. 2020: 435–443. doi: 10.1002/9781119436812.ch30
21.Gerresheim GK, Roeb E, Michel AM, et al. Hepatitis C virus downregulates core subunits of oxidative phosphorylation, reminiscent of the Warburg effect in cancer cells. Cells. 2019; 8(11): 1410. doi: 10.3390/cells8111410
22.Rodriguez D, Watts D, Gaete D, et al. Hypoxia pathway proteins and their impact on the blood vasculature. Int J Mol Sci. 2021; 22(17): 9191. doi: 10.3390/ijms22179191
23.Feng X, Shi Y, Zhang Y, et al. Opportunities and challenges for inhalable nanomedicine formulations in respiratory diseases: a review. Int J Nanomedicine. 2024; 19: 1509–1538. doi: 10.2147/IJN.S447492
24.Joseph AM, Al Aiyan A, Kumari R, et al. Role of Innate Immunity in Cancer. In: Innate Immunity: Pattern Recognition and Effector Mechanisms. 2025: 309–337.
25.Liu W, Wang B, Zhou M, et al. Redox dysregulation in the tumor microenvironment contributes to cancer metastasis. Antioxid Redox Signal. 2023; 39(7–9): 472–490. doi: 10.1089/ars.2023.0392
26.Shi D, Li Y, Tian M, et al. Nanomaterials-Based Drug Delivery Systems for Therapeutic Applications in Osteoporosis. Adv Biol. 2025; 9(2): 2400721. doi: 10.1002/adbi.202400721
27.Zhang Y, Yang M, Portney NG, et al. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed Microdevices. 2008; 10(2): 321–328. doi: 10.1007/s10544-007-9139-2
28.Soufiani KB, Pourfathollah AA, Zarifi MN, et al. Tumor microenvironment changing through application of MicroRNA-34a related mesenchymal stem cells conditioned medium: modulation of breast cancer cells toward non-aggressive behavior. Iran J Allergy Asthma Immunol. 2021; 20(5): 586–597. doi: 10.18502/ijaai.v20i5.7408
29.Li Y, Deng G, Hu X, et al. Recent advances in mesoporous silica nanoparticle-based targeted drug-delivery systems for cancer therapy. Nanomedicine. 2022; 17(18): 1253–1279. doi: 10.2217/nnm-2022-0131
30.Zhang P, Chen D, Li L, et al. Charge reversal nano-systems for tumor therapy. J Nanobiotechnology. 2022; 20(1): 31. doi: 10.1186/s12951-021-01221-8
31.Hu Y, Gao S, Khan AR, et al. Tumor microenvironment-responsive size-switchable drug delivery nanosystems. Expert Opin Drug Deliv. 2022; 19(3): 221–234. doi: 10.1080/17425247.2022.2041596
32.Song C, Li Y, Li T, et al. Long-Circulating Drug-Dye-Based Micelles with Ultrahigh pH-Sensitivity for Deep Tumor Penetration and Superior Chemo-Photothermal Therapy. Adv Funct Mater. 2020; 30(11): 1906309. doi: 10.1002/adfm.201906309
33.Nguyen TD, Jankowski E, Glotzer SC. Self-assembly and reconfigurability of shape-shifting particles. ACS Nano. 2011; 5(11): 8892–8903. doi: 10.1021/nn203012m
34.Sheng Y, Nesbitt H, Callan B, et al. Oxygen generating nanoparticles for improved photodynamic therapy of hypoxic tumours. J Control Release. 2017; 264: 333–340. doi: 10.1016/j.jconrel.2017.09.008
35.Lin X, Fang Y, Jin X, et al. Modulating repolarization of tumor-associated macrophages with targeted therapeutic nanoparticles as a potential strategy for cancer therapy. ACS Appl Bio Mater. 2021; 4(8): 5871–5896. doi: 10.1021/acsabm.1c00458
36.Su X, Li J, Xu X, et al. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. J Transl Med. 2024; 22(1): 751. doi: 10.1186/s12967-024-05558-w
37.Lu J, Feng F, Jin Z. Cancer diagnosis and treatment guidance: role of MRI and MRI probes in the era of molecular imaging. Curr Pharm Biotechnol. 2013; 14(8): 714–722. doi: 10.2174/1389201014666131226111612
38.Jiang M, Zhang K, Meng J, et al. Engineered exosomes in service of tumor immunotherapy: From optimizing tumor-derived exosomes to delivering CRISPR/Cas9 system. Int J Cancer. 2025; 156(5): 898–913. doi: 10.1002/ijc.35244
39.Manzotti C, Audisio RA, Pratesi G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis. 1993; 11(1): 5–14. doi: 10.1007/BF00880061
40.Shultz LD, Goodwin N, Ishikawa F, et al. Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014; 2014(7): pdb.top073585. doi: 10.1101/pdb.top073585
41.Portillo-Lara R, Annabi N. Microengineered cancer-on-a-chip platforms to study the metastatic microenvironment. Lab Chip. 2016; 16(21): 4063–4081. doi: 10.1039/c6lc00718j
42.Albritton JL, Miller JS. 3D bioprinting: improving in vitro models of metastasis with heterogeneous tumor microenvironments. Dis Model Mech. 2017; 10(1): 3–14. doi: 10.1242/dmm.025049
43.Mishra M, Ahmed R, Das DK, et al. Recent advancements in the application of circulating tumor DNA as biomarkers for early detection of cancers. ACS Biomater Sci Eng. 2024; 10(8): 4740–4756. doi: 10.1021/acsbiomaterials.4c00944
44.Boisson A, Noël G, Saiselet M, et al. Fluorescent multiplex immunohistochemistry coupled with other state-of-the-art techniques to systematically characterize the tumor immune microenvironment. Front Mol Biosci. 2021; 8: 673042. doi: 10.3389/fmolb.2021.673042
45.Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016; 1(5): 16014. doi: 10.1038/natrevmats.2016.14
46.Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012; 9(4): 199–207. doi: 10.1038/nrclinonc.2011.165
47.Jee J, Lebow ES, Yeh R, et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med. 2022; 28(11): 2353–2363. doi: 10.1038/s41591-022-02047-z
48.Pugliese R, Regondi S. Artificial intelligence-empowered 3D and 4D printing technologies toward smarter biomedical materials and approaches. Polymers. 2022; 14(14): 2794. doi: 10.3390/polym14142794
49.Mazumdar H, Khondakar KR, Das S, et al. Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes. Expert Opin Drug Deliv. 2025; 22(1): 85–108. doi: 10.1080/17425247.2024.2431857
50.Grinin L, Grinin A, Korotayev A. Medicine and the Cybernetic Revolution: On the Way to Control Over the Human Body. In: Cybernetic Revolution and Global Aging: Humankind on the Way to Cybernetic Society, or the Next Hundred Years. Heidelberg, Germany: Springer; 2024: 331–370.
